Introduction
============

Clear cell carcinoma (ccRCC) is the commonest subtype of renal cell carcinoma, accounting for 80% of cases. These tumours are highly resistant to cytotoxic chemotherapy and until recently, systemic treatment options for advanced ccRCC were limited to cytokine-based therapies, such as interleukin-2 and interferon-α. Recently, anti-angiogenic drugs and mTOR inhibitors, all targeting the HIF--VEGF axis which is activated in up to 91% of ccRCCs through loss of the VHL tumour suppressor gene [@b1], have been shown to be effective in metastatic ccRCC [@b2]--[@b5]. Although these drugs increase overall survival to more than 2 years [@b6], resistance invariably occurs, making the identification of new molecular targets a major clinical need to improve outcomes in patients with metastatic ccRCC.

In this study, we combined a genome-wide siRNA screen in a ccRCC cell line with analysis of a tumour versus normal tissue mRNA expression dataset to identify genes essential for, and strongly overexpressed in, ccRCC. We show that the lactate transporter MCT4/SLC16A3 is necessary for the survival of ccRCC cell lines and highly overexpressed in ccRCCs. MCT4 is required for lactate secretion, pH homoeostasis, and maintenance of the Warburg effect. The high level of MCT4 expression, particularly in metastatic and aggressive ccRCCs, together with a highly restricted expression pattern in normal tissues suggests the utility of MCT4 as a potential new drug target.

Materials and methods
=====================

Genome-wide siRNA screen
------------------------

RCC4 cells were transfected in 384 well plates and cell numbers determined with an Acumen Explorer (TTP Labtech, Melbourn, UK) after 4 days. A robust Z-score was calculated and smoothed for edge effects. Follow-up experiments were performed in 96-well plates and read similarly. Caspase 3/7 activity was determined with the Apo-ONE kit (Promega, Madison, WI, USA) and normalized with cell number.

mRNA expression analysis
------------------------

For the identification of siRNA screen hits overexpressed in ccRCC, expression data from GEO (GSE14994) were used. The meta-analysis of genes overexpressed in ccRCC and in metastatic versus primary tumours was performed and visualized on Oncomine™ (Compendia Bioscience, Ann Arbor, MI, USA). Expression of MCT1 and MCT4 in cancer cell lines was from the Cancer Genome Project cell line mRNA expression dataset (<http://www.sanger.ac.uk/genetics/CGP>).

Cell cycle profiling/sub-G1 analysis
------------------------------------

Cells were harvested and fixed in 70% ethanol, washed twice in phosphate--citrate buffer, and treated with RNase. DNA was stained with propidium iodide (50 µg/ml) and analysis was performed on a BD-LSRII flow cytometer. Cell populations with sub-G1 content were defined as apoptotic and cell cycle phases calculated using a Watson pragmatic model.

Metabolic assays
----------------

Lactate secretion after 2 h of incubation in pyruvate-free medium with 11 m[m]{.smallcaps} glucose and 2 m[m]{.smallcaps} glutamine was measured with a BioVision kit and normalized to cell mass measured with a sulphorodamine B assay (Sigma, St Louis, MO, USA).

Intracellular lactate concentrations were determined in equal numbers of cells washed with ice-cold PBS (pH 5), trypsinized, and then lysed with distilled water.

ATP levels were measured in equal numbers of viable cells using the ENLITEN® ATP Assay System (Promega).

Glycolysis and oxygen consumption rates were estimated by measuring extracellular acidification and oxygen consumption rates in a Seahorse XF96 (Seahorse Bioscience, North Billerica, MA,USA) extracellular flux analyser 3 days after siRNA transfection. Cells were assayed in XF medium with 2 g/l glucose.

Intracellular pH: cells were loaded with 10 µ[m]{.smallcaps} SNARF-4F (Molecular Probes, Eugene, OR, USA) and analysed in a BD-LSRII flow cytometer. The ratio between the 660 nm and the 585 nm emission was calculated after excitation with a yellow laser (561 nm) and a standard curve was built as described [@b7].

MCT4 expression analysis in ccRCC specimens
-------------------------------------------

Clinical samples immunostained for MCT4 expression were scored independently by two observers blinded to the associated clinical data as follows: 1 = no or minimal expression; 2 = weak staining; 3 = intermediate staining; 4 = strong staining. Highest and modal MCT4 expression was recorded for each sample. Relapse-free and overall survival was estimated using the Kaplan--Meier method from the time of surgery to relapse or from diagnosis of metastatic disease to death from any cause, respectively. Statistical significance was calculated by the log-rank test where appropriate. Follow-up was calculated for patients alive at the last follow-up.

Statistical analysis
--------------------

Student\'s *t*-test was used to compare the means of independent samples.

Supplementary materials and methods
-----------------------------------

Supplementary materials and methods may be found in the Supporting information.

Results
=======

A genome-wide siRNA screen targeting over 21 000 genes was performed in the VHL-deficient RCC4 cell line to identify essential genes for proliferation or survival of ccRCC cells. Cell numbers were measured 4 days after siRNA transfection and data were normalized and transformed into a Z-score indicating how many standard deviations the cell numbers of an individual experiment were above or below the median. Two hundred and ninety-seven genes had a Z-score of − 3 or below, indicating a statistically significant reduction in cell number ([Figure 1](#fig01){ref-type="fig"}A and Supporting information, Supplementary [Table 1](#SD5){ref-type="supplementary-material"}). In order to focus our analysis on genes that may be important in ccRCC biology, we investigated which of those were significantly overexpressed in 59 ccRCC tumour specimens in comparison to 11 normal kidney samples in a published mRNA expression dataset [@b8]. Fourteen of the 297 genes identified in the screen were among the 805 genes that were significantly overexpressed (≥ two-fold overexpression, FDR = 1%) in tumour samples ([Figures 1B and 1C](#fig01){ref-type="fig"}).

![(A) Genome-wide siRNA screen to identify genes required for proliferation and/or survival of RCC4 cells. Z-scores of cell numbers after 4 days of transfection are displayed. The red line indicates the cut-off (Z-score ≤− 3) for selection of hits. (B) Overlap between the 297 essential genes in RCC4 cells (Z-score ≤− 3) and the 805 genes overexpressed in clear cell renal carcinoma compared with normal kidney tissue. Expression data from ref 8. (C) Expression levels of the 14 genes identified in B in normal kidney and in ccRCC tumours, either wt or deficient for VHL. Values are log~2~ normalized to the median expression in the normal kidney samples. (D) Effect of silencing the 14 genes identified in B on proliferation of RCC4 and four non-ccRCC cell lines in genome-wide siRNA screens displayed as a heat map of the Z-scores. \*Genes whose silencing is detrimental in non-ccRCC cell lines. (E) *MCT4* is the seventh most overexpressed gene in ccRCC based on a meta-analysis of five different ccRCC expression datasets available in Oncomine [@b8], [@b23], [@b43]--[@b45]. Genes are ordered based on their median expression rank across the datasets. Berouk H and S refer to hereditary and sporadic ccRCCs from the Beroukhim dataset. (F) Comparison of *MCT1* and *MCT4* expression in ccRCC versus non-ccRCC cell lines. Normalized log~2~ expression is displayed as boxplots. The whiskers extend to the most extreme data point that is no more than 1.5 times the interquartile range from the box](path0227-0146-f1){#fig01}

Unpublished data from similar genome-wide siRNA screens previously performed in our High-Throughput Screening Laboratory in four non-ccRCC cell lines showed that ten out of the 14 genes had no significant anti-proliferative effects when silenced, suggesting that they may be ccRCC-specific survival regulators.

One of the genes identified through this approach was that encoding the Notch ligand JAG2. A literature search revealed that targeting Notch signalling with γ-secretase inhibitors attenuates the growth of ccRCC cell lines *in vitro* and *in vivo* [@b9]. Silencing of JAG2 reduced the cell number by 50--90% in a panel of eight ccRCC cell lines but not in the immortalized embryonic kidney cell line HEK293 (Supporting information, Supplementary [Figure 1A](#SD1){ref-type="supplementary-material"}); these were efficiently killed by the silencing of *PLK1* and *UBB* (Supporting information, Supplementary [Figure 1B](#SD1){ref-type="supplementary-material"}), validating our integrative functional genomics approach for therapeutic target identification.

Of the 14 overexpressed genes, *SLC16A3/MCT4* was the most highly and consistently overexpressed in both VHL-wild type and VHL-deficient ccRCCs ([Figure 1](#fig01){ref-type="fig"}C). A meta-analysis of five ccRCC expression datasets revealed that *MCT4* is the seventh most strongly overexpressed gene in this tumour type ([Figure 1](#fig01){ref-type="fig"}E). Expression analysis of a panel of 541 cancer cell lines comprising 12 tumour types revealed higher expression of *MCT4* in ccRCC relative to cell lines from other tumour entities. In contrast, expression levels of the related monocarboxylate transporter *SLC16A1/MCT1* were similar in all tumour types ([Figure 1](#fig01){ref-type="fig"}F).

Standard deconvolution techniques [@b10] were applied to validate the pool of four *MCT4* siRNAs used in the screen. The four individual siRNAs reduced *MCT4* mRNA levels and impaired proliferation to a similar degree to the pooled siRNAs (Supporting information, Supplementary [Figure 2A](#SD2){ref-type="supplementary-material"}). Comparable results were obtained with different *MCT4* siRNA sequences from another manufacturer (Supporting information, Supplementary [Figure 2B](#SD2){ref-type="supplementary-material"}). The reproducible correlation between the degree of mRNA knockdown and the anti-proliferative effect of all siRNAs indicates that *MCT4* silencing, rather than off-target effects attributable to individual siRNAs, led to the anti-proliferative effect.

MCT4 is one of four monocarboxylate transporters (MCT1--4) that shuttle pyruvate or lactate and protons across the plasma membrane in a gradient-dependent manner [@b11]. Most cancers display an increase in glucose usage and lactate secretion even in the presence of oxygen, a feature known as aerobic glycolysis or the Warburg effect (WE) [@b12], [@b13]. Based on substrate affinities and transport kinetics, MCT4 is assumed to be the main transporter responsible for the secretion of lactate out of highly glycolytic cells [@b14], [@b15]. *MCT1* and *MCT4* were expressed in all ccRCC cell lines, whereas HEK293 expressed only *MCT1* ([Figure 2](#fig02){ref-type="fig"}A). *SLC16A7/MCT2* and *SCL16A8/MCT3* were not detectable by qPCR (data not shown).

![(A) Q-PCR expression analysis of *MCT1* and *MCT4* in eight ccRCC cell lines and in the embryonic kidney cell line HEK293. Expression was normalized with *B*2*M* levels and represented as fold of expression in HEK293. Graphs show mean ± SD (*n* = 3). (B) Effect of *MCT1, MCT4*, and *CD147* silencing in a panel of eight ccRCC cell lines and in HEK293. Four days after transfection with siRNA, cell numbers were determined and normalized to non-targeting siRNAs. Graphs show mean ± SD (*n* = 6). \**p* \< 0.01; \*\**p* \< 0.001. (C) Expression of MCT4 and CD147 is co-dependent. RCC4 and A498 were transfected with siRNA,lysed after 3 days and used for western blot analysis. (D) *MCT4* silencing induces G2/M cell cycle arrest in RCC4 and 786-O. RCC4 and A498 were transfected with siRNA, stained with PI after 3 days, and analysed by FACS. Number represent the percentage of cells in sub-G1 and phases of the cell cycle. (E) *MCT4* silencing induces apoptosis in RCC4 and 786-O. Cells were transfected with siRNA and caspase 3/7 activity and cell numbers were determined after 4 days. Graphs show mean ± SD of caspase activity normalized to cell number in the same well (*n* = 3)](path0227-0146-f2){#fig02}

We further investigated the dependencies of ccRCC cells on *MCT1* and *MCT4* expression. Silencing *MCT4* significantly reduced proliferation in eight ccRCC cell lines tested, with no obvious distinction in sensitivity based on VHL status ([Figure 2](#fig02){ref-type="fig"}B, mean reduction 63%). Silencing of *MCT1* with a validated siRNA pool (Supporting information, Supplementary [Figure 2](#SD2){ref-type="supplementary-material"}C) in the same cell line panel significantly reduced the cell number in only four ccRCC cell lines ([Figure 2](#fig02){ref-type="fig"}B, mean reduction 30%). The embryonic kidney cell line HEK293 was insensitive to *MCT4* and *MCT1* silencing. Neither silencing of *MCT4* nor that of *MCT1* significantly affected the mRNA levels of the other transporter (Supporting information, Supplementary [Figure 2](#SD2){ref-type="supplementary-material"}D).

MCT1 and MCT4 form complexes with the ancillary protein CD147, which is required for protein expression and activity of both transporters [@b16]--[@b18]. *CD147* silencing has been described as a strategy to reduce the expression of both MCT1 and MCT4 [@b16]. Accordingly, MCT1 and MCT4 protein levels were decreased by *CD147* silencing ([Figure 2](#fig02){ref-type="fig"}C), which significantly impaired proliferation in six out of eight ccRCC cell lines ([Figure 2](#fig02){ref-type="fig"}B, mean reduction 42%). CD147 expression is lost after silencing *MCT4* but not *MCT1* ([Figure 2](#fig02){ref-type="fig"}C). Taken together, these data suggest that only the MCT4/CD147 complex is essential for proliferation and survival of ccRCC cells.

We next sought to investigate the mechanisms contributing to the reduction in cell number after *MCT4* silencing. Cell cycle profiling of ccRCC cell lines 4 days after *MCT4* silencing showed a G2/M-phase arrest and an increase in the apoptotic sub-G1 fraction compared with control transfected cells ([Figure 2](#fig02){ref-type="fig"}D). Apoptosis induction was confirmed by an increase in caspase 3/7 activity ([Figure 2](#fig02){ref-type="fig"}E). Thus, *MCT4* silencing results in both cytotoxic and cytostatic effects.

To confirm that the essential function of MCT4 in ccRCC model systems relates to its role in lactate secretion and in maintaining glycolysis, we investigated the metabolic consequences of MCT4 knockdown. Silencing of *MCT4* and *CD147* reduced lactate secretion in ccRCC cell lines, whereas *MCT1* silencing had no effect ([Figure 3](#fig03){ref-type="fig"}A). Lactate accumulated intracellularly following *MCT4* repression ([Figure 3](#fig03){ref-type="fig"}B), confirming that this transporter is important for lactate secretion in ccRCC cells. Measurements of the extracellular acidification and the oxygen consumption rates after silencing of *MCT4* or *CD147* revealed a reduction of glycolysis relative to oxygen consumption, indicating that MCT4/CD147 loss renders cells less glycolytic ([Figure 3](#fig03){ref-type="fig"}C).

![(A) *MCT4* and *CD147* silencing reduces lactate secretion in RCC4 and in A498. Following 2 days of transfection, cells were incubated in fresh medium for 2 h. Lactate secreted into the medium was quantified and normalized to cell mass content (siCtrl = 1 cell mass unit). Graph shows mean ± SD (*n* = 3). \**p* \< 0.05; \*\**p* \< 0.001. (B) *MCT4* silencing leads to intracellular accumulation of lactate in RCC4 and 786-O. Two days after transfection, an identical number of cells were lysed in water and lactate was quantified. Graphs show mean ± SD (*n* = 3). \**p* \< 0.05. (C) Silencing of *MCT4* impairs glycolysis in RCC4. Three days after transfection, extracellular acidification (ECAR) and oxygen consumption (OCR) rates were determined using a Seahorse XF96; the ratio between ECAR and OCR was calculated for each well. Graphs show mean ± SD (*n* = 6). \**p* \< 0.001. (D) *MCT4* silencing induces intracellular acidification in RCC4 and A498. Cells were loaded with SNARF-4F 2 days after transfection and analysed by FACS. The 660/585 nm emission ratio was determined after excitation with a yellow laser. A standard curve generated with cells incubated at pH 6, 7, and 8 was used to calculate the intracellular pH of each sample. Graphs show mean ± SD (*n* = 3). \**p* \< 0.05 versus both siCtrls. (E) *MCT4* silencing reduces ATP levels in RCC4 and 786-O. ATP levels were measured 2 days after siRNA transfection in identical cell numbers. Graphs show mean ± SD (*n* = 3). \**p* \< 0.01](path0227-0146-f3){#fig03}

MCTs contribute to intracellular pH regulation by co-transporting lactate together with a proton [@b19]. Silencing of *MCT4*, but not *MCT1*, decreased intracellular pH in two ccRCC cell lines by 0.2 and 0.25 units, respectively ([Figure 3](#fig03){ref-type="fig"}D), indicating that MCT4 is important to maintain pH homeostasis. *MCT4* silencing also decreased cellular ATP levels ([Figure 3](#fig03){ref-type="fig"}E), which may be a consequence of the inhibition of glycolysis by intracellular acidification [@b20].

To further demonstrate that ccRCCs require MCT4 to excrete glucose-derived lactate, we investigated the effect of silencing MCT4 in cells growing in glucose-free medium. ccRCC cell lines proliferated less in the absence of glucose, and silencing of *MCT4* under these conditions had a blunted effect on proliferation compared with glucose-replete conditions ([Figure 4](#fig04){ref-type="fig"}A), while suppression of *PLK1*, a gene essential for mitosis [@b21], was equally detrimental in both conditions. ccRCC cells were also grown in the presence of 150 m[m]{.smallcaps} exogenous lactate. Since MCT4 is a passive co-transporter that shuttles lactate and protons in the direction of transmembrane gradients [@b11], this led to the accumulation of lactate intracellularly ([Figure 4](#fig04){ref-type="fig"}B). Incubation in these conditions reduced proliferation ([Figure 4](#fig04){ref-type="fig"}C) and led to the accumulation of cells in G2/M ([Figure 4](#fig04){ref-type="fig"}D), mimicking the effect of *MCT4* silencing. Taken together, these observations indicate that ccRCC cells depend on MCT4 expression to eliminate lactate produced by glycolysis.

![(A) Glucose depletion reduces sensitivity of RCC4 and 786-O to *MCT4* silencing. Cells were transfected as indicated and incubated either in glucose-free or in medium with 25 (RCC4) or 11 (786-O) m[m]{.smallcaps} glucose. Four days after transfection, cell number was determined. Graphs show mean ± SD (*n* = 6). (B) Addition of lactate to the medium induces accumulation of intracellular lactate in RCC4 and 786-O. Two days after incubation in the presence or absence of 150 m[m]{.smallcaps} lactate, an identical number of cells were lysed in water and lactate was quantified. Graphs show mean ± SD (*n* = 3). \**p* \< 0.01. (C) Addition of lactate to the medium reduces proliferation of RCC4 and 786-O. Cells were grown in the presence of the indicated concentrations of lactate. After 4 days, cell number was determined. Graphs show mean ± SD (*n* = 12). \**p* \< 0.05; \*\**p* \< 0.001. (D) Addition of lactate to the medium induces G2 arrest in RCC4 and 786-O. Cells were grown in the presence of the indicated concentrations of lactate, DAPI-stained, and analysed on an Acumen Explorer eX3](path0227-0146-f4){#fig04}

MCT4 protein expression was assessed by immunostaining 127 surgical primary ccRCC specimens. MCT4 staining intensity was scored on a scale from 1 (lowest expression) to 4 (highest expression; for details see the Materials and methods section). Examples of staining intensities are shown in [Figure 5](#fig05){ref-type="fig"}A. MCT4 expression was detectable in the majority of ccRCC samples ([Figure 5](#fig05){ref-type="fig"}B), consistent with mRNA expression data ([Figure 1](#fig01){ref-type="fig"}C). Whereas stromal expression of MCT4 has been shown in breast cancer [@b22], in ccRCCs the stromal compartment was predominantly MCT4-negative (arrows in [Figure 5](#fig05){ref-type="fig"}A). The cancer cells in many specimens displayed heterogeneous MCT4 staining ([Figure 5](#fig05){ref-type="fig"}C) and both the modal and the highest staining intensities were recorded ([Figure 5](#fig05){ref-type="fig"}B).

![(A) ccRCC FFPE specimens demonstrating representative MCT4 staining intensities (original magnification 20×). Arrows indicate stromal cells. (B) Distribution of modal and highest MCT4 staining intensities in 127 primary ccRCC tumours. (C) ccRCC FFPE specimens demonstrating intra-tumoural heterogeneity in MCT4 staining intensity (original magnification 20×). (D) Correlation between modal MCT4 staining intensity and Fuhrman tumour grade. Pearson correlation coefficient (*r*) was calculated (*n* = 127). (E) Relapse-free survival (RFS) by highest observed MCT4 staining in tumour specimens of patients treated surgically for early-stage ccRCC (low = MCT4 staining intensity 1 or 2; high = MCT4 staining intensity 3 or 4). (F) *MCT4* mRNA expression in primary ccRCC versus metastatic ccRCC versus normal kidney specimens. Expression data from ref 23](path0227-0146-f5){#fig05}

Modal MCT4 expression was highly correlated with Fuhrman nuclear grade ([Figure 5](#fig05){ref-type="fig"}D, *p* \< 0.001). Relapse-free survival (RFS) analysis in 46 patients with early-stage disease treated with potentially curative surgery and for whom follow-up data were available showed a significantly worse RFS in patients with tumours showing MCT4 staining intensities of 3 or 4 ([Figure 5](#fig05){ref-type="fig"}E, *p* = 0.017). The difference in RFS was only apparent if tumours were categorized based on the highest observed MCT4 expression within the samples but not when categorized based on the modal staining intensity. This may indicate that a subset of ccRCC cells with high MCT4 expression has an increased ability to disseminate from a heterogeneous primary tumour. This was further supported by significantly higher *MCT4* mRNA expression levels in metastatic ccRCC lesions compared with primary tumours ([Figure 5](#fig05){ref-type="fig"}F), consistent with the colonization of metastatic sites by subclones with high MCT4 expression. Neither modal nor highest MCT4 expression in the primary tumour correlated with overall survival in 50 patients with metastatic disease (Supporting information, Supplementary [Figure 3](#SD3){ref-type="supplementary-material"}).

To evaluate potential toxicities of MCT4 targeting approaches, we immunostained several normal tissues for MCT4; high expression was found only in skeletal muscle, bone marrow, and Brunner\'s glands of the duodenum (Supporting information, Supplementary [Figure 4](#SD4){ref-type="supplementary-material"}). Taken together, these data suggest the potential of MCT4 targeting to limit ccRCC growth.

Discussion
==========

We integrated whole-genome siRNA screening, mRNA expression analysis, and metabolic assays to identify the monocarboxylate transporter MCT4 as a potential novel therapeutic target in ccRCC. *MCT4* was the seventh most overexpressed gene in ccRCC and its overexpression was independent of VHL status. MCT4 abrogation reduced lactate secretion, intracellular pH and ATP levels, and led to G2/M arrest and apoptosis in ccRCC cell lines. High-level expression of MCT4 in primary tumours correlated with poor RFS, and metastatic lesions displayed higher MCT4 protein expression than primary tumours. Taken together, these data suggest the potential of MCT4 to serve as a novel therapeutic target in ccRCC. Importantly, the discovery of an MCT1/MCT2 isoform-specific inhibitor [@b24], [@b25] suggests that isoform-specific targeting of MCT4 may also be possible.

MCT4\'s main function is the secretion of lactate and protons from highly glycolytic cells [@b15]. High rates of glucose uptake and lactate secretion are features of the WE that contribute to support ATP production and provide intermediates for biosynthesis in many tumours [@b12], [@b13], [@b26]. Inactivation of the VHL tumour suppressor gene leads to the stabilization of hypoxia-inducible factor 1 alpha (HIF1α), which induces the WE and up-regulates the direct HIF1α target MCT4 [@b27]. Aerobic glycolysis can also be induced by oncogene activation, such as *MYC* amplification, or loss of certain tumour suppressors such as PTEN [@b28], both of which are known to occur in ccRCC [@b29], [@b30]. This may explain our observations that *MCT4* expression is independent of VHL status in ccRCC.

*MCT4* knockdown, but not silencing of the related MCT1 transporter, impaired proliferation of all the ccRCC cell lines tested, indicating that ccRCCs depend strongly on MCT4 rather than MCT1 for survival. We have demonstrated through a series of metabolic assays that *MCT4* knockdown impairs the cell\'s ability to secrete the weak acid lactate, which consequently leads to a reduction in intracellular pH. A similar decrease in pH has been shown to increase caspase activation by two- to three-fold [@b31], which is consistent with the induction of apoptosis that we observed after *MCT4* silencing. The reduction in ATP levels is also a potential consequence of this alteration in the acid--base balance [@b20]. Accumulation of intracellular lactate may also inhibit its conversion from pyruvate by lactate dehydrogenase [@b32], the main reaction regenerating NAD^+^ in highly glycolytic cells [@b33]. Silencing of *MCT4* also led to a G2/M cell cycle arrest, indicating that there may be additional links between metabolism and cell cycle progression apart from those described recently [@b34].

*MCT4* silencing led to a concomitant loss in the expression of CD147, an ancillary protein necessary for MCT activity [@b35] that is required for *in vivo* growth of colon carcinoma [@b16] and pancreatic [@b36] cancer cells. Although CD147 interacts with other proteins, it has been shown that its major pro-tumour role is to control MCT1/4 activity [@b16]. This is in agreement with our observation that high concentrations of lactate in the medium, which led to the accumulation of intracellular lactate, reduced cell viability and impaired cell cycle progression, phenocopying the consequences of *MCT4* silencing. Conversely, glucose withdrawal, which reduces lactate production, attenuated the effect of *MCT4* knockdown. Thus, it is likely that the accumulation of intracellular lactate is responsible for the impact on cell viability after *MCT4* silencing, rather than loss of another function attributable to CD147.

Silencing or pharmacological inhibition of MCT1 in colon cancer cells has been shown to be effective only in the absence of MCT4 expression, indicating functional redundancy of MCT1 and MCT4 [@b16]. In contrast, our results highlight an essential and non-redundant function of MCT4 in ccRCC. Higher expression of MCT4 in ccRCC cell lines compared with several other tumour types may be indicative of a higher dependence on aerobic glycolysis and thus on the MCT4 isoform, optimized for lactate secretion. A decisive advantage of an MCT4 isoform-specific inhibitor for ccRCC therapeutic use would be the highly restricted expression in normal body tissues in comparison to the ubiquitously expressed MCT1 [@b11]. High-level expression of MCT4 in muscle tissue could be a potential hurdle to therapeutic targeting.

The presence of ccRCC cells with high-level expression of MCT4 in tumour specimens correlated with relapse-free survival after surgery for early-stage cancers. This association with RFS was only observed when tumours were scored for the highest MCT4 expression rather than modal MCT4 expression, suggesting that intra-tumour heterogeneity may impact on phenotypic differences in metastatic potential. This is consistent with reports showing that high MCT4 expression and lactate secretion increase cell motility and invasive potential in *in vitro* models of breast [@b17] and lung [@b37] cancer, and that MCT4 causes extracellular acidification in xenografts [@b38], which may contribute to matrix degradation and invasion (reviewed in ref [@b39]).

Recent studies demonstrated that aerobic glycolysis in tumour cells can be targeted through inhibition of the glucose transporter GLUT1 [@b40], LDH-A [@b41] or PFKFB3 [@b42]. Our study shows that the inhibition of lactate elimination through MCT4 targeting may be a novel strategy to target tumour-specific metabolic alterations such as the WE. The development of inhibitors specific to the MCT4 isoform would be a prerequisite to examine this hypothesis in patients with ccRCC. Such developments might add a novel therapeutic class of agents, which target tumour metabolism, for the treatment of kidney cancer.
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SUPPORTING INFORMATION ON THE INTERNET
======================================

The following supporting information may be found in the online version of this article.

**Supplementary materials and methods**

**Table S1.** Results of a genome-wide siRNA screen for survival regulators in the RCC4 cell line.

**Figure S1.** (A) A panel of renal cell carcinoma cell lines is highly sensitive to silencing of JAG2. (B) Silencing of PLK1 and UBB efficiently reduce cell numbers in HEK293 4 days after transfection.

**Figure S2.** (A) Effect of MCT4 silencing on cell number correlates well with silencing efficiency. (B) MCT4 silencing phenotype is also observed using different siRNA sequences obtained from another manufacturer. (C) The effect of silencing MCT1 on cell number is not significant despite efficient silencing. (D) MCT1 and MCT4 silencing is specific.

**Figure S3.** Overall survival (OS) by highest and modal MCT4 staining intensity in tumour specimens of patients with metastatic disease treated with a palliative nephrectomy.

**Figure S4.** MCT4 expression in normal tissues (20×).
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